A Non-interventional Study to Assess the Influence of Automated Optical Coherence Tomography Image Enrichment With Segmentation Information on Disease Activity Assessment in Patients Treated With Licensed Anti- VEGF Injections (RAZORBILL)
A Non-interventional Study to Assess the Influence of Automated Optical Coherence Tomography (OCT) Image Enrichment With Segmentation Information on Disease Activity Assessment in Patients Treated With Licensed Anti- VEGF Injections
Sponsor: Novartis Pharmaceuticals
Listed as NCT04662944, this observational or N/A phase trial focuses on Neovascular Age-Related Macular Degeneration and remains completed. Sponsored by Novartis Pharmaceuticals, it has been updated 22 times since 2021, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
22 versions recorded-
Sep 2025 — Present [monthly]
Completed
-
Sep 2024 — Sep 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Aug 2023 — Jul 2024 [monthly]
Completed
Status: Active Not Recruiting → Completed
-
Jul 2023 — Aug 2023 [monthly]
Active Not Recruiting
▶ Show 17 earlier versions
-
May 2023 — Jul 2023 [monthly]
Active Not Recruiting
-
Apr 2023 — May 2023 [monthly]
Active Not Recruiting
-
Dec 2022 — Apr 2023 [monthly]
Active Not Recruiting
-
Nov 2022 — Dec 2022 [monthly]
Active Not Recruiting
-
Sep 2022 — Nov 2022 [monthly]
Active Not Recruiting
Status: Recruiting → Active Not Recruiting
-
Jul 2022 — Sep 2022 [monthly]
Recruiting
-
Jun 2022 — Jul 2022 [monthly]
Recruiting
-
May 2022 — Jun 2022 [monthly]
Recruiting
-
Jan 2022 — May 2022 [monthly]
Recruiting
-
Dec 2021 — Jan 2022 [monthly]
Recruiting
-
Nov 2021 — Dec 2021 [monthly]
Recruiting
-
Sep 2021 — Nov 2021 [monthly]
Recruiting
-
May 2021 — Sep 2021 [monthly]
Recruiting
-
Apr 2021 — May 2021 [monthly]
Recruiting
Status: Not Yet Recruiting → Recruiting
-
Mar 2021 — Apr 2021 [monthly]
Not Yet Recruiting
-
Feb 2021 — Mar 2021 [monthly]
Not Yet Recruiting
-
Jan 2021 — Feb 2021 [monthly]
Not Yet Recruiting
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Novartis Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Barcelona, Spain , Bonn, Germany , Bormujos, Spain , Düsseldorf, Germany , Glasnevin, Ireland , Göttingen, Germany , Hamilton, Canada , León, Spain , Ludwigsburg, Germany , Milan, Italy and 5 more locations